Luteinizing hormone–releasing hormone (LH–RH) antagonist Cetrorelix inhibits growth of DU-145 human androgen-independent prostate carcinoma in nude mice and suppresses the levels and mRNA expression of IGF-II in tumors

This publication has 33 references indexed in Scilit:

• Luteinizing hormone-releasing hormone antagonist Cetrorelix (SB-75) and bombesin antagonist RC-3940-II inhibit the growth of androgen-independent PC-3 prostate cancer in nude mice
  The Prostate, 1997
• Inhibition of growth of androgen-independent DU-145 prostate cancer in vivo by luteinising hormone-releasing hormone antagonist cetrorelix and bombesin antagonists RC-3940-II and RC-3950-II
  European Journal Of Cancer, 1997
• Cancer statistics, 1996
  CA: A Cancer Journal for Clinicians, 1996
• Somatostatin receptors in human prostate and prostate cancer
  Journal of Clinical Endocrinology & Metabolism, 1995
• Regulation of endometrial cancer cell growth by insulin-like growth factors and the luteinizing hormone-releasing hormone antagonist SB-75
  Regulatory Peptides, 1993
• Luteinizing hormone-releasing hormone antagonists interfere with autocrine and paracrine growth stimulation of MCF-7 mammary cancer cells by insulin-like growth factors
  Journal of Clinical Endocrinology & Metabolism, 1993
• Present status of agonistic and antagonistic analogs of LH-RH in the treatment of advanced prostate cancer
  Biomedicine & Pharmacotherapy, 1992
• IGF-1 Receptor as the Restriction Point of the Cell Cycle
  Annals of the New York Academy of Sciences, 1992
• Editorial: The Possible Autocrine/Paracrine and Endocrine Roles of Insulin-Like Growth Factors of Human Tumors
  Endocrinology, 1990
• Inhibition of Access of Bound Somatomedin to Membrane Receptor and Immunobinding Sites: A Comparison of Radioreceptor and Radioimmunoassay of Somatomedin in Native and Acid-Ethanol-Extracted Serum*
  Journal of Clinical Endocrinology & Metabolism, 1980